HC Wainwright & Co. Reiterates Buy on Elicio Therapeutics, Maintains $23 Price Target
HC Wainwright & Co. analyst Robert Burns reiterates Elicio Therapeutics (NASDAQ:ELTX) with a Buy and maintains $23 price target.
Read original at benzingaStocks · News reference
8-K filing — Elicio Therapeutics, Inc. (ELTX)
Filed: 2026-08-13 AccNo: 0001601485-26-000055 Size: 2 MB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- edgar
- Observed
- Aug 13, 2026, 8:06 PM
- Checked
- Aug 13, 2026, 8:06 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Elicio Therapeutics Q2 EPS $(0.43) Beats $(0.54) Estimate
Elicio Therapeutics (NASDAQ:ELTX) reported quarterly losses of $(0.43) per share which beat the analyst consensus estimate of $(0.54) by 20.37 percent. This is a 34.85 percent increase over losses of $(0.66) per share
Read original at benzingaElicio Therapeutics Announces Opening Of 20-Patient Investigator-Initiated Phase 1 Trial Of ELI-002 7P With Chemotherapy, Anti-PD1 In Neoadjuvant Pancreatic Cancer At Memorial Sloan Kettering
Read original at benzinga